BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$75.89

Market cap

$13.91B

P/E Ratio

16.43

Dividend/share

N/A

EPS

$4.62

Enterprise value

$14.35B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
BMRN's quick ratio has surged by 61% year-on-year
The equity has grown by 31% YoY
Biomarin Pharmaceutical's gross profit has decreased by 6% YoY but it has increased by 3.3% QoQ
BMRN's gross margin is down by 10% year-on-year

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
183.35M
Market cap
$13.91B
Enterprise value
$14.35B
Valuations
Price to earnings (P/E)
16.43
Price to book (P/B)
3.27
Price to sales (P/S)
7.24
EV/EBIT
N/A
EV/EBITDA
213.68
EV/Sales
7.49
Earnings
Revenue
$1.92B
EBIT
-$42.05M
EBITDA
$67.16M
Free cash flow
$173.42M
Per share
EPS
$4.62
Free cash flow per share
$0.95
Book value per share
$23.21
Revenue per share
$10.48
TBVPS
$29.03
Balance sheet
Total assets
$5.9B
Total liabilities
$1.66B
Debt
$1.08B
Equity
$4.24B
Working capital
$1.91B
Liquidity
Debt to equity
0.25
Current ratio
5.32
Quick ratio
3.49
Net debt/EBITDA
6.49
Margins
EBITDA margin
3.5%
Gross margin
70.7%
Net margin
43.7%
Operating margin
-3.3%
Efficiency
Return on assets
14.1%
Return on equity
20.2%
Return on invested capital
-0.8%
Return on capital employed
-0.8%
Return on sales
-2.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-2.1%
1 week
-2.49%
1 month
-1.79%
1 year
-2.29%
YTD
-13.46%
QTD
-1.81%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$1.92B
Gross profit
$1.35B
Operating income
-$64.02M
Net income
$837.21M
Gross margin
70.7%
Net margin
43.7%
Biomarin Pharmaceutical's operating margin has increased by 48% from the previous quarter
The operating income has increased by 45% since the previous quarter
BMRN's gross margin is down by 10% year-on-year
Biomarin Pharmaceutical's gross profit has decreased by 6% YoY but it has increased by 3.3% QoQ

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
16.43
P/B
3.27
P/S
7.24
EV/EBIT
N/A
EV/EBITDA
213.68
EV/Sales
7.49
BMRN's P/E is 6% below its last 4 quarters average of 17.5
Biomarin Pharmaceutical's EPS has increased by 5% QoQ
The stock's price to book (P/B) is 35% less than its 5-year quarterly average of 5.0 and 7% less than its last 4 quarters average of 3.5
The equity has grown by 31% YoY
BMRN's price to sales (P/S) is 30% less than its 5-year quarterly average of 10.3 and 7% less than its last 4 quarters average of 7.8
The revenue has grown by 3.9% from the previous quarter and by 3.8% YoY

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's return on sales has shrunk by 149% YoY but it has surged by 57% QoQ
Biomarin Pharmaceutical's ROIC has plunged by 136% YoY but it has soared by 58% from the previous quarter
BMRN's return on assets is up by 2.2% since the previous quarter

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
The company's current ratio has surged by 63% YoY
BMRN's quick ratio has surged by 61% year-on-year
The debt is 75% smaller than the equity
BMRN's debt to equity is down by 44% year-on-year and by 3.8% since the previous quarter
The equity has grown by 31% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.